WinstonWınston
Stemsation International logo

Stemsation International

STSN
Drug Manufacturers - Specialty & Generic · Healthcare
Price
$0.01
+0.00 (+16.98%)
Market Cap
$1.1M
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+230.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 187.8M (2021) → 620.5M (2025)

Stemsation International, Inc. is a small healthcare company focused on stem cell-related products and wellness supplements. Its offerings appear to target consumers and practitioners interested in cellular health and regenerative wellness. The company operates in the specialty health products space, which sits at the edge of mainstream pharmaceutical and nutraceutical markets.

Stemsation generates revenue primarily through direct product sales, though its financials show essentially no gross profit and negative returns on capital, suggesting the business is in an early or struggling stage. It appears to operate mainly in North America with a limited commercial footprint. The core risk facing Stemsation is its lack of demonstrated revenue traction and profitability — a zero gross margin signals the company has not yet built a sustainable business model, and it faces significant competition from larger, better-funded companies in both the supplement and regenerative medicine spaces.

Winston Score History

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
N/A
Data not available
Operating Margin
N/A
Data not available
ROCE
-0.2%
Weak — -0.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
N/A
Data not available
EPS YoY
N/A
Data not available
EPS Consistency
2/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.10
Conservative — low debt load (0.10)
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
19.1x
Fair value — P/E 19.1

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial